Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Clinical trial NCT05110157 · COMPLETED
Trial details
- NCT number
- NCT05110157
- Sponsor
- Neurocrine Biosciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-29
- Primary completion
- 2025-02-04
- Enrollment
- 442
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.